ALK and non-small cell lung carcinoma: These results extend the picture of adverse clinical outcome associated with TP53 mutations in ALK+ NSCLC, and demonstrate the great potential of ctDNA assays for molecular profiling and longitudinal monitoring in ALK+ NSCLC beyond detection of ALK resistance mutations.